• news.cision.com/
  • ChemoTech/
  • Scandinavian ChemoTech signs agreement with AIIMS Jodhpur, to establish a Centre of Excellence (CoE) as part of the India Sweden Healthcare Innovation Centre

Scandinavian ChemoTech signs agreement with AIIMS Jodhpur, to establish a Centre of Excellence (CoE) as part of the India Sweden Healthcare Innovation Centre

Report this content

After a solid process, which was delayed by the pandemic, ChemoTech has now reached a long-awaited milestone by establishing a Centre of Excellence "CoE" at the India Sweden Healthcare Innovation Centre. This Innovation Centre is physically located at the All India Institute of Medical Sciences (AIIMS) Jodhpur and is part of the state cooperation in health care between Sweden and India and is an initiative that is co-financed by the Swedish and Indian states.

This agreement means that AIIMS Jodhpur and ChemoTech, through this CoE, will conduct clinical studies with the aim of creating clinical data and evidence for the effect of TSE treatment on various cancers. The first studies are planned to start during Q2-Q3 2022 and mainly include head andneck cancer, which accounts for approx. 30–40% 1.2 of all cancer cases in India (total number of cancer cases amounts to about 1.4 million cases3).

It is of great importance to ChemoTech that AIIMS now chooses to collaborate through the India-Sweden Healthcare Innovation Centre and thereby ensures access to ChemoTech ‘s technology and the opportunity to gather knowledge in order to build a CoE. ChemoTech will contribute with two IQwave systems. One system shall be dedicated to clinical studies and one for the training of future doctors in medical education, which constitutes an essential part of the institute's activities.

“We are very grateful for the help we have received through the government initiatives; The Embassy of Sweden in Delhi, and Business Sweden who run the Innovation Centre; also Swecare and the Sweden India Business Council have all contributed to this process. For the company, this is a very big step forward, which indicates that the general healthcare system in India also understands the unique opportunities that TSE can contribute to cancer care in India.” - says Mohan Frick, CEO of ChemoTech

1 Manik Rao Kulkarni, IJHNS, 2013;4(1):29-35
2 Bhattacharjee A et al., IJOHNS 2006;58:15-19
3 Mathur P et al., JCO Glob Oncol, 2020;6:1063-1075

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 11-11-2021 11:30 CET.

For more information, please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00


Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00E-mail: certifiedadviser@penser.se

India-Sweden Healthcare Innovation Centre
The India-Sweden Healthcare Innovation Centre is a tripartite collaboration between AIIMS Delhi, AIIMS Jodhpur and Swedish Trade Commissioner’s office (Business Sweden) and knowledge partners AstraZeneca, NASSCOM and Vision Zero Cancer. The collaboration is envisioned to develop an ecosystem of open innovation by identifying problem statements of mutual interest which the healthcare delivery stakeholders can use to collaborate and address current and future challenges in the healthcare sector in India & Sweden. This platform enables collaboration through development of Centres of Excellences, Skilling, and Capacity Building and by also working with Start-ups toward Scaleup of solutions for affordable and accessible healthcare in line with the objectives of the Government of India. For more information, please visit: www.indiaswedenic.com

Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.




Documents & Links